Trends in live birth prevalence of Down syndrome in the Northern Netherlands 1987-96: The impact of screening and prenatal diagnosis

Prenatal Diagnosis

Volumn 20, Issue 9, 2000, Pages 709-713

  Wortelboer, M J M ^a,b   De Wolf, B T H M ^a   Verschuuren Bemelmans, C C ^a   Reefhuis, J ^a   Mantingh, A ^a   Beekhuis, J R ^a   Cornel, M C ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cost benefit; Down syndrome; Live birth prevalence; Maternal serum screening; Prenatal diagnosis

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CYTOGENETICS; DIAGNOSTIC VALUE; DOWN SYNDROME; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MATERNAL AGE; MATERNAL BLOOD; NEWBORN; POPULATION RESEARCH; PRENATAL DIAGNOSIS; PRIORITY JOURNAL;

ADULT; AGE FACTORS; COST-BENEFIT ANALYSIS; DOWN SYNDROME; FEMALE; HUMAN; INFANT, NEWBORN; MASS SCREENING; MATERNAL AGE; NETHERLANDS; PREGNANCY; PRENATAL DIAGNOSIS; PREVALENCE; RISK FACTORS;

EID: 0033807121     PISSN: 01973851     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0223(200009)20:9<709::AID-PD910>3.0.CO;2-J     Document Type: Article

References (20)

1. Maternal serum screening for fetal neural tube defects and Down's syndrome; first experience
2. Prevention of congenital anomalies: Policy in the Netherlands
3. Trends in prenatal diagnosis of Down Syndrome and other autosomal trisomies in Scotland 1990 to 1994, with associated cytogenetic and epidemiological findings
4. Down syndrome in the North-East Netherlands; expectations and reality 1981-1986
5. Down syndrome: Effects of demographic factors and prenatal diagnosis on the future livebirth prevalence
6. Impact of a regional screening programme using maternal serum α-fetoprotein (AFP) and human chorionic gonadotrohpin (hCG) on the birth incidence of Down's syndrome in the west of Scotland
7. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level
8. Better understanding of factors influencing uptake is needed
9. Trends in Down's syndrome prevalence in California, 1983-1988
10. New estimates of Down syndrome risks at chorionic villous sampling, amniocentesis, and livebirth in women of advanced maternal age from a uniquely defined population
11. Birth prevalence of Down's syndrome in England and Wales 1990 to 1997
12. Serum screening for foetal Down's syndrome of pregnant women with an indication for prenatal diagnosis because of age: Fewer amniocenteses
13. Nuchal translucency cannot be used as a screening test for chromosomal abnormalities in the first trimester of pregnancy in a routine ultrasound practice
14. Prenatal Diagnosis in the Netherlands
15. Fetal nuchal translucency: Ultrasound screening for fetal trisomy in the first trimester of pregnancy
16. The impact of Antenatal screening for Down syndrome in Western Australia. 1980-1994
17. First-trimester fetal nuchal translucency thickness and risk for trisomies
18. Appraisal of a new scheme for prenatal screening for Down's syndrome
19. A demographic approach to the assessment of Down syndrome screening performance
20. Maternal serum screening for Down's syndrome in early pregnancy